Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Other demographical, clinical, and serological features are shown on Table 1.Clinical and serological features of patients classified with Idiopathic Inflammatory Myopathies in our study group.Clinical or serological featureMen (n = 4)Women (n = 8)Both (n = 12)P*Age (years,\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{\mathrm{x }}\pm \mathrm{S }.\mathrm{D}.$$\end{document}x¯±S.D.)39.5 ± 18.1944.7 ± 14.2843.0 ± 15.060.461#MMT8 (score, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{\mathrm{x }}\pm \mathrm{S }.\mathrm{D}.$$\end{document}x¯±S.D.)137.5 ± 21.19144.6 ± 5.50142.2 ± 12.410.972#CPK (U/L, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{\mathrm{x }}\pm \mathrm{S }.\mathrm{D}.$$\end{document}x¯±S.D.)232.2 ± 219.29346.87 ± 695.07308.7 ± 568.980.570#Aldolase (U/L, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{\mathrm{x }}\pm \mathrm{S }.\mathrm{D}.$$\end{document}x¯±S.D.)5.07 ± 3.303.5 ± 2.064.2 ± 2.540.629#AST (U/L, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{\mathrm{x }}\pm \mathrm{S }.\mathrm{D}.$$\end{document}x¯±S.D.)39.2 ± 21.7327.5 ± 12.9031.4 ± 16.380.715#ALT (U/L, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{\mathrm{x }}\pm \mathrm{S }.\mathrm{D}.$$\end{document}x¯±S.D.)62.4 ± 46.6722.3 ± 9.4735.6 ± 32.280.117#LDH (U/L, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{\mathrm{x }}\pm \mathrm{S }.\mathrm{D}.$$\end{document}x¯±S.D.)173.3 ± 30.01253.0 ± 96.79229.1 ± 89.030.383#CRP (mg/L, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{\mathrm{x }}\pm \mathrm{S }.\mathrm{D}.$$\end{document}x¯±S.D.)6.3 ± 7.2010.5 ± 16.858.9 ± 13.800.927#ESR (mm/h, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{\mathrm{x }}\pm \mathrm{S }.\mathrm{D}.$$\end{document}x¯±S.D.)12.2 ± 15.3530.0 ± 15.8223.5 ± 17.350.048#Personal historyDiabetes n(%): : : : Hypertension n(%)1 (25.0): 1 (8.3): Alcohol n(%)2 (50.0): 2 (16.7): Smoke n(%)3 (75.0): 3 (25.0): Drugs n(%)2 (50.0): 2 (16.7): Extramuscular manifestationsArthritis n (%)1 (25.0)2 (25.0)3 (25.0): Arthralgia n (%): 4 (50.0)4 (33.3): Joint contracture n (%): : : : Mechanic's hands n (%): : : : Raynaud's phenomenon n (%): 2 (25.0)2 (16.7): Heliotrope n (%)1 (25.0)1 (12.5)2 (16.7): Gottron's sign n (%)1 (25.0)1 (12.5)2 (16.7): Shawl sign n (%): 1 (12.5)1 (8.3): V sign n (%)1 (25.0)2 (25.0)3 (25.0): Periungual erythema n (%)1 (25.0): 1 (8.3): Ulceration n (%): : : : Gastrointestinal perforation n (%): : : : Abdominal pain n (%): : : : Dysphagia n (%)1 (25.0)1 (12.5)2 (16.7): Calcinosis n (%): 1 (12.5)1 (8.3): Interstitial lung disease n (%)1 (25.0)3 (37.5)4 (33.3): Pulmonary fibrosis n (%)2 (50.0)2 (25.0)4 (33.3): Pulmonary hypertension n (%): 1 (12.5)1 (8.3): Vasculitis n (%): : : : Arrhythmias n (%): : : : Cardiomyopathy n (%): : : : Myocardial infarction n (%): : : : Associated cancer n (%): 1 (25.0)1 (8.3): TreatmentMethotrexate n (%)2 (50.0)7 (87.5)9 (75.0)0.300&Prednisone n (%)3 (75.0)5 (62.5)8 (66.7) > 0.999&Hydroxychloroquine n (%)1 (25.0)3 (37.5)4 (33.3): Mycophenolate n (%)1 (25.0)2 (25.0)3 (25.0): Azathioprine n (%): 1 (12.5)1 (8.3): SupplementFolic acid n (%)2 (50.0)6 (75.0)8 (66.7) > 0.999&Vitamin D n (%)3 (75.0)3 (37.5)6 (50.0)0.200&IIM idiopathic inflammatory myopathies; \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{x}$$\end{document}x¯ mean; S.D. standard deviation; MMT8 Manual Muscle Testing 8; CPK creatine phosphokinase; AST aspartate aminotransferase; ALT alanine aminotransferase; LDH lactate dehydrogenase; CRP C-reactive protein; ESR erythrocyte sedimentation rate.*Only the characteristics of men and women were included in the statistical analysis.#Mann: Whitney U with Fisher's Exact test.&Fisher's exact for contingency tables test.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Menchaca” were enrolled in this cross-sectional study.

Source: Methods.

Patients were grouped according to histological features in connective tissue increased, diffuse and multifocal atrophy, perifascicular atrophy, perivascular inflammatory infiltrate, endomysial inflammatory infiltrate, degenerated fibers, necrotic fibers, basophilic fibers, edema and bleeding, muscle fiber size variation, endothelial hyperplasia, and tumefaction.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Impaired muscle strength is associated with ultrastructure damage in myositis

Cross-sectional study · Scientific Reports · 2022

Original publication title

Impaired muscle strength is associated with ultrastructure damage in myositis

Andrea Aguilar-Vazquez; Efrain Chavarria-Avila; Mario Salazar-Paramo; Juan Armendariz-Borunda; Guillermo Toriz-González; Marcela Rodríguez-Baeza; Ana Sandoval-Rodriguez; Arisbeth Villanueva-Pérez; Marisol Godínez-Rubí; Jose-David Medina-Preciado; Ingrid Lundberg; Yesenia Lozano-Torres; Cynthia-Alejandra Gomez-Rios; Oscar Pizano-Martinez; Erika-Aurora Martinez-Garcia; Beatriz-Teresita Martin-Marquez; Sergio Duran-Barragan; Brenda-Lucia Palacios-Zárate; Arcelia Llamas-Garcia; Livier Gómez-Limón; Monica Vazquez-Del Mercado

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

The muscle fiber ultrastructure in Idiopathic Inflammatory Myopathies (IIM) has been scarcely explored, especially in Inclusion Body Myositis. The aim of this study was to implement the Scanning Electron Microscopy (SEM) in a small cohort of IIM patients, together with the characterization of immunological profile for a better understanding of the pathophysiology. For immunological profile characterization, we identified the presence of autoantibodies (Ro-52, OJ, EJ, PL7, PL12, SRP, Jo-1, PMScl75, PMScl100, Ku, SAE1, NXP2, MDA5, TIF1γ, Mi-2α, Mi-2β) and quantified cytokines (IL-1β, IFN-α2, IFN-γ, TNF-α, IL-6, IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33) and chemokines (CCL2, CXCL8).

The histological analysis was made by hematoxylin: eosin staining while the muscle fiber ultrastructure was characterized by SEM. We observed changes in the morphology and structure of the muscle fiber according to muscle strength and muscle enzymes. We were able to find and describe muscle fiber ultrastructure with marked irregularities, porosities, disruption in the linearity and integrity of the fascicle, more evident in patients with increased serum levels of muscle enzymes and diminished muscle strength. Despite the scarce reports about the use of SEM as a tool in all clinical phenotypes of IIM, our work provides an excellent opportunity to discuss and reframe the clinical usefulness of SEM in the diagnostic approach of IIM.

Authors’ abstract

The muscle fiber ultrastructure in Idiopathic Inflammatory Myopathies (IIM) has been scarcely explored, especially in Inclusion Body Myositis. The aim of this study was to implement the Scanning Electron Microscopy (SEM) in a small cohort of IIM patients, together with the characterization of immunological profile for a better understanding of the pathophysiology. For immunological profile characterization, we identified the presence of autoantibodies (Ro-52, OJ, EJ, PL7, PL12, SRP, Jo-1, PMScl75, PMScl100, Ku, SAE1, NXP2, MDA5, TIF1γ, Mi-2α, Mi-2β) and quantified cytokines (IL-1β, IFN-α2, IFN-γ, TNF-α, IL-6, IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33) and chemokines (CCL2, CXCL8).

The histological analysis was made by hematoxylin: eosin staining while the muscle fiber ultrastructure was characterized by SEM. We observed changes in the morphology and structure of the muscle fiber according to muscle strength and muscle enzymes. We were able to find and describe muscle fiber ultrastructure with marked irregularities, porosities, disruption in the linearity and integrity of the fascicle, more evident in patients with increased serum levels of muscle enzymes and diminished muscle strength. Despite the scarce reports about the use of SEM as a tool in all clinical phenotypes of IIM, our work provides an excellent opportunity to discuss and reframe the clinical usefulness of SEM in the diagnostic approach of IIM.

Publication and source details

Original title: Impaired muscle strength is associated with ultrastructure damage in myositis

Andrea Aguilar-Vazquez; Efrain Chavarria-Avila; Mario Salazar-Paramo; Juan Armendariz-Borunda; Guillermo Toriz-González; Marcela Rodríguez-Baeza; Ana Sandoval-Rodriguez; Arisbeth Villanueva-Pérez; Marisol Godínez-Rubí; Jose-David Medina-Preciado; Ingrid Lundberg; Yesenia Lozano-Torres; Cynthia-Alejandra Gomez-Rios; Oscar Pizano-Martinez; Erika-Aurora Martinez-Garcia; Beatriz-Teresita Martin-Marquez; Sergio Duran-Barragan; Brenda-Lucia Palacios-Zárate; Arcelia Llamas-Garcia; Livier Gómez-Limón; Monica Vazquez-Del Mercado

Scientific Reports · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Fondo de Desarrollo Cientifico (FODECIJAL) 2019 from Consejo Estatal de Ciencia y Tecnología de Jalisco (COECYTJAL)1702512-8152Vazquez-Del Mercado Monica

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T22:03:53.305442+00:00

DOI: 10.1038/s41598-022-22754-4 · PMC9586957